Combination treatments in Alzheimer's disease: Risks and benefits

Expert Review of Neurotherapeutics

Volumn 10, Issue 5, 2010, Pages 693-702

  Sobow, Tomasz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Alzheimer's disease; Cholinesterase inhibitor; Combination therapy; Ginkgo biloba; Memantine; Statin; Treatment; Vitamin B; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; CYANOCOBALAMIN; DONEPEZIL; FOLIC ACID; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; NEUROTRANSMITTER; OMEGA 3 FATTY ACID; PIRACETAM; PLACEBO; RASAGILINE; RIVASTIGMINE; SELEGILINE; TARENFLURBIL; VITAMIN B GROUP;

ADD ON THERAPY; ALZHEIMER DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEADACHE; HUMAN; NAUSEA AND VOMITING; NEUROTRANSMISSION; PARKINSON DISEASE; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; CHOLINESTERASE INHIBITORS; CLINICAL TRIALS AS TOPIC; COGNITION DISORDERS; EXCITATORY AMINO ACID ANTAGONISTS; FATTY ACIDS, OMEGA-3; HUMANS; MEMANTINE; NEUROPSYCHOLOGICAL TESTS; RISK; VITAMINS;

EID: 77951795122     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.10.43     Document Type: Review

References (82)

1. Minati L, Edginton T, Bruzzone TG, Giaccone G. Current concepts in Alzheimer's disease: a multidisciplinary review. Am. J. Alzheimers Dis. Other Dement. 24 (2), 95-121 (2008).
2. Jalbert JJ, Daiello LA, Lapane KK. Dementia of Alzheimer type. Epidemiol. Rev. 30, 15-34 (2008).
3. Moreira PI, Zhu X, Nunomura A, Smith MA, Perry G. Therapeutic options in Alzheimer's disease. Expert Rev. Neurother. 6 (6), 897-910 (2006). (Pubitemid 43961890)
4. Pepeu G, Giovannini MM. Cholinesterase inhibitors and beyond. Curr. Alzheimer Res. 6 (2), 86-96 (2009).
5. Francis PP. Glutamatergic approaches to the treatment of cognitive and behavioral symptoms of Alzheimer's disease. Neurodegener. Dis. 5 (3-4), 241-243 (2008). (Pubitemid 351347861)
6. Pakaski M, Kalman J. Interactions between the amyloid and cholinergic mechanism in Alzheimer's disease. Neurochem. Int. 53 (5), 103-111 (2008).
7. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhitbits and reverses the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS Lett. 566 (1-3), 261-269 (2004). (Pubitemid 38625969)
8. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RR. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res. Ther. 1 (2), 7 (2009).
9. Shanks M, Kivipelto M, Bullock R, Lane R. Cholinesterase inhbition: is there evidence for disease-modifying effects? Curr. Med. Res. Opin. 25 (10), 2439-2446 (2009).
10. Fox C, Maidment ID, Boustani M, Katona C. Memantine combined with an acetyl cholinesterase inhibitor - hope for the future? Neuropsychiatr. Dis. Treat. 2 (2), 121-125 (2006). (Pubitemid 44043605)
11. Vidal JS, Lacombe JM, Dartigues JF et al. Memantine therapy for Alzheimer Disease in real-world practice. An observational study in a large representative sample of French patients. Alzheimer Dis. Assoc. Disord. 22 (2), 125-130 (2008).
12. Weinstein AM, Barton C, Ross L, Kramer JH, Yaffe K. Treatment practices of mild cognitive impairment in California Alzheimer's Disease Centers. J. Am. Geriatr. Soc. 57 (4), 686-690 (2009).
13. Froelich L, Andreasen N, Tsolaki M et al. Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an internationale survey. Curr. Med. Res. Opin. 25 (12), 3059-3068 (2009).
14. Danysz W, Parsons CG, Moebius HJ, Stoeffer A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's disease. Neurotox. Res. 2 (2-3), 85-97 (2000).
15. Zheng F, Johnson SS. Metabotropic glutamate and muscarinic cholinergic receptor-mediated preferential inhibition of N-methyl-d-aspartate component of transmission in rat ventral tegmental area. Neuroscience 116 (4), 1013-1020 (2003). (Pubitemid 36262959)
16. Flores-Fernandez J, Salgado H, De La Rosa V et al. Cholinergic direct inhibition of N-methyl-d-aspartate receptor-mediated currents in the rat neocortex. Synapse 63 (4), 308-318 (2009).
17. Francis PP. The interplay of neurotransmitters in Alzheimer's disease. CNS Spectr. 10 (11 Suppl. 18), 6-9 (2005).
18. Geerts H, Grossberg GG. Pharmacology of acetylcholinestarase inhibitors and N-methyl-d-aspartate receptors for combination therapy in the treatment of Alzheimer's disease. J. Clin. Pharmacol. 46 (7 Suppl. 1), S8-S16 (2006). (Pubitemid 43882807)
19. 1 nicotinic acetylcholine receptors more potently than N-methyl-d-aspartate receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 312 (3), 1195-1205 (2005). (Pubitemid 40293781)
20. Ramnes G, Danysz W, Parsons CC. Pharmacodynamics of memantine: an update. Curr. Neuropharmacol. 6 (1), 55-78 (2008). (Pubitemid 351513473)
21. Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WW. Lack of pharmacokinetic interaction between memantine and donepezil. Ann. Pharmacother. 38 (9), 1389-1394 (2004)
22. Yao C, Raoufnia A, Gold M et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J. Clin. Pharmacol. 45 (5), 519-528 (2005). (Pubitemid 40562942)
23. Shua-Haim J, Smith J, Picard F et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study. Clin. Drug Invest. 28 (6), 361-374 (2008). (Pubitemid 351685393)
24. Tariot PN, Farlow MR, Grossberg GT et al. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized, controlled trial. JAMA 291 (3), 317-324 (2004). (Pubitemid 38101604)
25. Porsteinsson A P, Grossberg GT, Mintzer J, Olin JT for the Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr. Alzheimer Res. 5 (1), 83-89 (2008).
26. Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int. J. Geriatr. Psychiatry 25 (4), 419-426 (2010).
27. Farlow MR, Alva G, Meng X, Olin JJ. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-tomoderate Alzheimer's disease: a post hoc analysis. Curr. Med. Res. Opin. 26 (2), 263-269. (2010).
28. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to beneft from previous cholinesterase inhibitor treatment. Int. J. Clin. Pract. 60 (1), 110-118 (2006). (Pubitemid 43732587)
29. th Alzheimer's Association International Conference on Alzheimer's Disease. Chicago, IL, USA, 26-31 July 2008.
30. th Alzheimer's Association International Conference on Alzheimer's Disease. Chicago, IL, USA, 26-31 July 2008.
31. th Alzheimer's Association International Conference on Alzheimer's Disease. Chicago, IL, USA, 26-31 July 2008.
32. th Alzheimer's Association International Conference on Alzheimer's Disease. Vienna, Austria, 11-16 July 2009.
33. Cummings JL, Schneider LS, Tariot PN, Graham SM; Memantine MEM-MD-02 Study Group. Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 67 (1), 57-63 (2006).
34. van Dyck CH, Schmitt FA, Olin JJ. A responder analysis of memantine treatment in patients with Alzheimer's disease maintained on donepezil. Am. J. Geriatr. Psychiatry 14 (5), 428-437 (2006).
35. Schmitt FA, van Dyck CH, Wichems CH, Olin JJ. Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory re-analysis. Alzheimer Dis. Assoc. Disord. 20 (4), 255-262 (2006).
36. Feldman HH, Schmitt FA, Olin JJ. Activities of daily living in moderate-tosevere Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis. Assoc. Disord. 20 (4), 263-268 (2006).
37. Atri A, Shaughnessy LW, Locascio JJ, Growdon JJ. Long-term course and effectiveness of combination therapy in Alzheimer Disease. Alzheimer Dis. Assoc. Disord. 22 (3), 209-221 (2008).
38. Lopez OL, Becker JT, Wahed AS et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J. Neurol. Neurosurg. Psychiatry 80 (6), 600-607 (2009).
39. Reisberg B, Doody R, Stoeffer A, Schmitt F, Ferris S, Moebius HH. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch. Neurol. 63 (1), 49-54 (2006). (Pubitemid 43063861)
40. Morris MM. The role of nutrition in Alzheimer's disease: epidemiological evidence. Eur. J. Neurol. 16 (Suppl. 1), 1-7 (2009).
41. Feart C, Samieri C, Rondeau V et al. Adherence to a Mediterrean diet, cognitive decline, and risk of dementia. JAMA 302 (6), 638-648 (2009).
42. Scarmeas N, Luchsinger JA, Schupf N et al. Physical activity, diet, and risk of Alzheimer disease. JAMA 302 (6), 627-637 (2009).
43. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336 (17), 1216-1222 (1997). (Pubitemid 27183651)
44. Sobow T, Kloszewska I. Donepezil plus vitamin E as a treatment in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 17 (4), 244 (2003). (Pubitemid 37517793)
45. Petersen RC, Thomas RG, Grundman M et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352 (23), 2379-2388 (2005). (Pubitemid 40958434)
46. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and metaanalysis. JAMA 297 (8), 842-857 (2007). (Pubitemid 46333949)
47. Pavlik VN, Doody RS, Rountree SD, Darby EE. Vitamin E use is associated with improved survival in an Alzheimer's Disease Cohort. Dement. Geriatr. Cogn. Disord. 28 (6), 536-540 (2009).
48. Connelly PJ, Prentice NP, Cousland G, Bonham J. A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease. Int. J. Geriatr. Psychiatry 23 (2), 155-160 (2008). (Pubitemid 351308495)
49. Aisen PS, Schneider LS, Sano M et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA 300 (15), 1774-1783 (2008).
50. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch. Neurol. 63 (10), 1402-1408 (2006). (Pubitemid 44547551)
51. Freund-Levi Y, Basun H, Cederholm T et al. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int. J. Geriatr. Psychiatry 23 (2), 161-169 (2008). (Pubitemid 351308496)
52. Magyar K, Palf M, Jenei V, Szoko E. Deprenyl: from chemical synthesis to neuroprotection. J. Neural Transm. Suppl. 71, 143-156 (2006). (Pubitemid 351412116)
53. Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst. Rev. 1, CD000442 (2003).
54. Youdim MB, Bar Am O, Yogev-Falach M et al. Rasagilne: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J. Neurosci. Res. 79 (1-2), 172-179 (2005). (Pubitemid 40116432)
55. Kelley BJ, Knopman DD. Alternative medicine and Alzheimer's disease. Neurologist 14 (5), 299-306 (2008).
56. Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J. Clin. Pharmacol. 44 (5), 538-542 (2004). (Pubitemid 38509723)
57. Yancheva S, Ihl R, Nikolova G et al. Ginkgo biloba extract EGb 761 (R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment. Health 13 (2), 183-190 (2009).
58. Szekely CA, Town T, Zandi PP. NSAIDs for the chemoprevention of Alzheimer's diseae. Subcell. Biochem. 42, 229-248 (2007).
59. Henderson V W. Action of estrogens in the aging brain: dementia and cognitive aging. Biochim. Biophys. Acta DOI: 10.1016/j. bbagen. 2009.11.005 (2009) (Epub ahead of print).
60. Rockwood K. Epidemiological and clinical trials evidence about a preventive role for statins in Alzheimer's disease. Acta Neurol. Scand. Suppl. 185, 71-77 (2006). (Pubitemid 44015228)
61. Kandiah N, Feldman HH. Therapeutic potential of statins in Alzheimer's disease. J. Neurol. Sci. 283 (1-2), 230-234 (2008).
62. De Jong D, Jansen R, Hoefnagels W et al. No effect of one-year treatment with indomethacin on Alzheimer's disease progression: a randomized controlled trial. PLoS One 3 (1), e1475 (2008). (Pubitemid 351796317)
63. Reines SA, Block GA, Morris JC et al. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 62 (1), 66-71 (2004).
64. Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289 (21), 2819-2826 (2003). (Pubitemid 37430117)
65. Wilcock GK, Black SE, Hendrix SB et al. Effcacy and safety of tarenfurbil in mild to moderate Alzheimer's disease: a randomised Phase II trial. Lancet Neurol. 7 (6), 483-493 (2008).
66. Green RC, Schneider LS, Amato DA et al. Effect of tarenfurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302 (23), 2557-2564 (2009).
67. Schneider LS, Farlow M. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease. Ann. NY Acad. Sci. 826, 317-322 (1997). (Pubitemid 27478052)
68. Laine K, Palovaara S, Tapanainen P, Manninen P. Plasma tacrine concentrations are signifcantly increased by concomitant hormone replacement therapy. Clin. Pharmacol. Ther. 66 (6), 602-608 (1999). (Pubitemid 30014087)
69. Rigaud AS, Andre G, Vellas B, Touchon J, Pere JJ; French Study Group. No additional beneft of HRT on response to rivastigmine in menopausal women with AD. Neurology 60 (1), 148-149 (2003).
70. Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A. Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol. Scand. Suppl. 185, 63-70 (2006). (Pubitemid 44015227)
71. Sparks DL, Connor DJ, Sabbagh MN, Petersen RB, Loez J, Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity infuence the beneft of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. Scand. Suppl. 185, 3-7 (2006). (Pubitemid 44015218)
72. Jones RW, Kivipelto M, Feldman H et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe) : design and baseline characteristics. Alzheimers Dement. 4 (2), 145-153 (2008).
73. Flirski M, Sobow T. Biochemical markers and risk factors of Alzheimer's disease. Curr. Alzheimer Res. 2 (1), 47-64 (2005). (Pubitemid 41389259)
74. Cummings JJ. Defning and labelling disease-modifying treatments for Alzheimer's disease. Alzheimers Dement. 5 (5), 406-418 (2009).
75. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 6 (8), 734-746 (2007). (Pubitemid 47058377)
76. Lovestone S, Francis P, Kloszewska I et al. AddNeuroMed - the European collaboration for the discovery of novel biomarkers for Alzheimer's disease. Ann. NY Acad. Sci. 1180, 36-46 (2009).
77. Petersen RC, Aisen PS, Beckett LA et al. Alzheimer's Disease Neuroimaging Initiative (ADNI). Clinical characterization. Neurology 74 (3), 201-209 (2010).
78. Jones R, Sheehan B, Phillips P et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials 10, 57 (2009).
79. Bell KF, Bennett DA, Cuello AA. Paradoxical upregalation of glutamatergic presynaptic boutons during mild cognitive impairment. J. Neurosci. 27 (40), 20810-20817 (2007).
80. Sobow T, Kloszewska I. Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials. Neurol. Neurochir. Pol. 41 (1), 13-21 (2007). (Pubitemid 46390713)
81. Ravaglia G, Forti P, Lucicesare A et al. Plasma tocopherols and risk of cognitive impairment in an elderly Italian cohort. Am. J. Clin. Nutr. 87 (5), 1306-1313 (2008). (Pubitemid 351679774)
82. Doody RS, Gavrilova SI, Sano M et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372 (9634), 207-215 (2008). (Pubitemid 351978110)